SWX:SDZPharmaceuticals
Assessing Sandoz Group (SWX:SDZ) Valuation After Strong 2025 Results And Biosimilar Growth Milestones
Sandoz Group (SWX:SDZ) has drawn fresh attention after reporting full year 2025 earnings, with sales of US$11,086 million and net income of US$914 million, alongside progress in its expanding biosimilars portfolio.
See our latest analysis for Sandoz Group.
Sandoz Group's 1 day share price return of 2.87% contrasts with a 7 day share price return of 4.64% and a 90 day share price return of 24.01%. The 1 year total shareholder return of 80.41% points to strong momentum around its biosimilars...